MGUS and Asymptomatic Multiple Myeloma (AMM)

2013-05 A Phase II Study of Autologous Expanded Natural Killer Cell (ENK) Therapy for Asymptomatic Multiple Myeloma (AMM)

Principal Investigator: Dr. Frits van Rhee

Primary Objectives:

Determine whether significant in vivo expansion of autologous ENK cells occurs;

Determine the safety of the ENK cell therapy in research participants with high-risk AMM

Secondary Objective:

Determine whether autologous ENK cell therapy can delay progression from AMM to symptomatic multiple myeloma

Eligibility:

Patients with high-risk Asymptomatic Multiple Myeloma


2011-61 A Prospective Observational Study of Patients with Monoclonal Gammopathy (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Principal Investigator: Dr. Kahn

Objectives:

To establish a serum, cell and tissue bank of prospectively collected samples from patients with MGUS, asymptomatic multiple myeloma, and other closely related disorders;

To assess the feasibility of accruing patients with this disease;

To assess the feasibility of accruing patients with this disease;

To evaluate if patterns of gene expression or cytogenetics exist that allow molecular delineation of “MGUS subtypes”;

To study DNA/CIg content by flow cytometry of these patients to identify aneuploidy patterns